Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study

Background Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep venous thrombosis (DVT), can be life threatening. An increased frequency of VTE has been found in inflammatory conditions. To date, evidence assessing whether this risk is also greater in patients with ankylosing spondylitis (AS) is scarce. Methods Using the provincial British Columbia, Canada healthcare database that encompasses all residents within the province, we conducted matched cohort analyses of incident PE, DVT and overall VTE among incident cases of AS and compared them with individuals randomly selected from the general population without AS. We calculated incidence rates (IRs) of VTE and multivariable analyses after adjusting for traditional risk factors using Cox models. Results Among 7190 incident cases of AS, 35 developed PE and 47 developed DVT. IRs of PE, DVT and overall VTE per 1000 person-years for patients with AS were 0.79, 1.06, 1.56 compared with 0.40, 0.50, 0.77 in the control cohort. Corresponding fully adjusted HRs (95% CI) of PE, DVT and VTE were 1.36 (0.92 to 1.99), 1.62 (1.16 to 2.26) and 1.53 (1.16 to 2.01), respectively. The risks of PE, DVT and VTE were highest in the first year of diagnosis with HR (95% CI) of 2.88 (0.87 to 9.62), 2.20 (0.80 to 6.03) and 2.10 (0.88 to 4.99), respectively. Conclusions These findings demonstrate an increased risk of VTE in the general AS population. This risk appears the most prominent in the first year after diagnosis.

[1]  Daniel B. Shin,et al.  Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study , 2018, European heart journal.

[2]  L. Jacobsson,et al.  Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study , 2017, Arthritis Research & Therapy.

[3]  Hyon K. Choi,et al.  The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Primary Sjögren Syndrome: A General Population-based Study , 2017, The Journal of Rheumatology.

[4]  Linda C. Li,et al.  Public opinion on community-based education and exercise programs for managing hip and knee osteoarthritis-like symptoms: results of a survey , 2016, Patient preference and adherence.

[5]  Hyon K. Choi,et al.  Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A General Population‐Based Study , 2016, Arthritis care & research.

[6]  Linda C. Li,et al.  Femoroacetabular impingement and osteoarthritis of the hip. , 2015, Canadian family physician Medecin de famille canadien.

[7]  Hyon K. Choi,et al.  The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study. , 2015, Seminars in arthritis and rheumatism.

[8]  Jenny Leese,et al.  Rheumatologists’ Views and Perceived Barriers to Using Patient Decision Aids in Clinical Practice , 2015, Arthritis care & research.

[9]  J. Paterson,et al.  Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality , 2015, Annals of Internal Medicine.

[10]  M. González-Gay,et al.  Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients , 2015, Rheumatology International.

[11]  C Allyson Jones,et al.  Emerging Role of Quality Indicators in Physical Therapist Practice and Health Service Delivery , 2015, Physical Therapy.

[12]  S. Schneeweiss,et al.  Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. , 2015, The American journal of medicine.

[13]  Hyon K. Choi,et al.  The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study , 2014, Annals of the rheumatic diseases.

[14]  Hyon K. Choi,et al.  Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study , 2014, Annals of the rheumatic diseases.

[15]  D. Shi,et al.  Comparison of Venous Thromboembolism after Total Hip Arthroplasty between Ankylosing Spondylitis and Osteoarthritis , 2014, BioMed research international.

[16]  Michal Dolezel,et al.  Erratum to “New Optical Methods for Liveness Detection on Fingers” , 2014, BioMed research international.

[17]  S. Schneeweiss,et al.  Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis , 2013, Arthritis care & research.

[18]  M. Ghajarzadeh,et al.  Successful Catheter-Directed Venous Thrombolysis in an Ankylosing Spondylitis Patient with Phlegmasia Cerulea Dolens , 2013, Iranian journal of radiology : a quarterly journal published by the Iranian Radiological Society.

[19]  P. Voulgari,et al.  Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. , 2013, Clinical and experimental rheumatology.

[20]  Hyon K. Choi,et al.  The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study , 2012, Annals of the rheumatic diseases.

[21]  R. White.  Identifying risk factors for venous thromboembolism. , 2012, Circulation.

[22]  E. Horváth-Puhó,et al.  Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population‐based case‐control study , 2012, Journal of thrombosis and haemostasis : JTH.

[23]  M. Etminan,et al.  Oral fluoroquinolones and the risk of retinal detachment. , 2012, JAMA.

[24]  J. Sundquist,et al.  Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden , 2012, The Lancet.

[25]  A. Levy,et al.  Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. , 2011, Arthritis & Rheumatism.

[26]  D. Symmons,et al.  Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti‑TNF therapy: results from the British Society for Rheumatology Biologics Register , 2011, Annals of the rheumatic diseases.

[27]  S. Schneeweiss,et al.  Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. , 2011, JAMA.

[28]  P. Szodoray,et al.  Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. , 2011, Autoimmunity reviews.

[29]  M. Abrahamowicz,et al.  Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study , 2011, Annals of the rheumatic diseases.

[30]  M. Abrahamowicz,et al.  Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: a population-based study , 2011, Annals of the rheumatic diseases.

[31]  Sreeram V Ramagopalan,et al.  Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study , 2011, BMC medicine.

[32]  B. Dijkmans,et al.  Signs of Accelerated Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis , 2010, The Journal of Rheumatology.

[33]  Zoran Bursac,et al.  Purposeful selection of variables in logistic regression , 2008, Source Code for Biology and Medicine.

[34]  J. Heit,et al.  The epidemiology of venous thromboembolism in the community. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[35]  J. Singh,et al.  Accuracy of the diagnoses of spondylarthritides in veterans affairs medical center databases. , 2007, Arthritis and rheumatism.

[36]  C. Huerta,et al.  Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. , 2007, Archives of internal medicine.

[37]  P. Romundstad,et al.  Incidence and mortality of venous thrombosis: a population‐based study , 2007, Journal of thrombosis and haemostasis : JTH.

[38]  S. Schneeweiss.  Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.

[39]  P. Merkel,et al.  Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study , 2005, Annals of Internal Medicine.

[40]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[41]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[42]  J. Nolla,et al.  Antiphospholipid syndrome in patients with ankylosing spondylitis. , 1993, Journal of Rheumatology.

[43]  J. Nolla,et al.  [Antiphospholipid syndrome in patients with ankylosing spondylitis. Presentation of 2 cases]. , 1992, Medicina clínica (Ed. impresa).

[44]  I. Lazareth,et al.  Lupus anticoagulant and leg ulcers associated with ankylosing spondylitis. , 1991, The Journal of rheumatology.

[45]  M. Abrahamowicz,et al.  Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. , 2013, Rheumatology.

[46]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.